Research Interests for Henry G. Grabowski

Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives to Innovate: An International Comparative Analysis” with John Vernon and Lacy Glenn Thomas, to his more recent projects including, “Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention” with Jeffrey L. Moe. His latest research studies include other such titles as, “Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity” with Margaret Kyle; “Should the Patent System for New Medicines Be Abolished?” with J.A. DiMasi; and several others. Professor Grabowski has served as an advisor and consultant to various organizations, offering his ideas and insights gained through his extensive investigations to the National Trade Academy of Sciences, the Institute of Medicine, the Office of Technology Assessment, the Federal Trade Commission, and the General Accounting Office. His latest project involved an analysis for the FTC concerning public policy, competition and investment in the “Next Generation of Biologics.”

Current projects:

Testimony and Public Policy Comments

Recent Publications

1. with Margaret Kyle, Richard Mortimer, Genia Long and Noam Kirson, Evolving Brand-Name and Generic Competition May Warrant a Revision of the Hatch-Waxman Act, Health Affairs, vol. 30 no. 11 (November, 2011), pp. 2157-2166
2. The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection, International Journal of the Economics of Business, vol. 18 no. 2 (July, 2011), pp. 161-176
3. with Genia Long and Richard Mortimer, Data Exclusivity for Biologics, Nature Reviews Drug Discovery, vol. 10 no. 1 (January, 2011), pp. 15-16 (PDF also includes the on-line supplementary material published in connection with this article..)
4. with Joseph DiMasi, R&D Costs and Returns, in The Handbook of Pharmaceuticals, edited by OPatricia Danzon and Sean Nichols (2011), Oxford University Press (Forthcoming.)
5. with Genia long and Richard Mortimer, Implementation of the Biosimilar Pathway: Economic and Policy Issues, Seton Hall Law Review, vol. 41 no. 2 (2011), pp. 511-557